In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...
Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated ...
QIAGEN today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research. The ...
Although heart cells and skin cells contain identical instructions for creating proteins encoded in their DNA, they're able ...
AZoLifeSciences on MSN
Weill Cornell Scientists Develop Safe and Precise Tool to Control Gene Activity
Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...
Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...
A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...
Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback